Linked Life Data

8018408

Source:http://linkedlifedata.com/resource/pubmed/id/8018408

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-8-4
pubmed:abstractText
In the athymic nude mice model with xenotransplanted human carcinomas, the effect of a monoclonal antibody (MAb 425), directed against the human epidermal growth factor (EGFR), on tumour growth was studied. Five different solid human breast carcinomas and one vulvar epidermoid cancer cell line (A431) were transplanted in nude mice, and treated with MAb 425 2.2 mg intraperitoneally (i.p.) on day 7 post-transplantation. Tumours with EGFR concentrations of > or = 16 fmol/mg soluble cytosolic protein showed growth inhibition, whereas the growth pattern of EGFR-negative tumours was unaffected. Variation of MAb 425 dosage (1.1 versus 2.2 mg) revealed no difference in the growth inhibiting effect. Different application schedules (application on day 0, 12 or 26) showed different onsets and durations of tumour growth inhibition. Repeated application (1.1 mg, day 0 and 12) was followed by a prolonged inhibitory effect. Our results suggest that growth inhibition of EGFR-positive tumours by MAb 425 may lead to an additional treatment option for patients with EGFR-positive cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
30A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
491-6
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor.
pubmed:affiliation
Department of Gynecology and Gynecologic Oncology, Frankfurt University Medical Center, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't